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Shabneez Hussain* and Salman Naseem AdilAbstract
Background: Fanconi’s anemia (FA) is an inherited bone marrow failure syndrome that carries a higher risk of
transformation to acute myeloid leukemia (AML) when compared with general population. AML is the initial
presentation in approximately one third of patients.
Case presentation: A 17 year old male presented to the emergency room with history of high grade fever since
two weeks. Examination revealed pallor, short stature and thumb polydactyly. There was no visceromegaly or
lymphadenopathy. Complete blood count showed haemoglobin 3.4 gm/dl, MCV 100 fl and MCH 36 pg, white
blood cell count 55.9 × 10 E9/L and platelet count 8 × 10E9/L. Peripheral blood smear revealed 26% blast cells. Bone
marrow was hypercellular exhibiting infiltration with 21% blast cells. Auer rods were seen in few blast cells. These
findings were consistent with acute myelomonocytic leukemia. These blasts cells expressed CD33, CD13, HLA-DR,
CD117, CD34 antigens and cytoplasmic myeloperoxidase on immunophenotyping. Bone marrow cytogenetics
revealed 46, XY, t (8:21) (q22; q22) [11] / 46, XY, add (2) (q37), t (8; 21) [4] / 46, XY [5]. Molecular studies showed
positivity of FLT 3 D835 variant and negativity of NPM 1 and FLT3 ITD (internal tandem domain) mutation.
Peripheral blood analysis for chromosomal breakage exhibited tri-radial and complex figures. He received induction
chemotherapy with cytarabine and daunorubicin (3 + 7). Day 14 marrow revealed clearance of blast cells.
Conclusion: The recognition of specific cytogenetic abnormalities present in FA known to predispose to AML is
crucial for early haematopoietic stem cell transplant (HSCT) before transformation to leukemia.
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Fanconi anemia (FA) is an autosomal recessive disease
which is the most frequent cause of inherited bone marrow
failure syndromes. These patients usually present in the
first and second decade of life [1] with bone marrow failure
and various congenital abnormalities such as short stature,
skin hyperpigmentation such as “cafe´-au-lait spots”,
Fanconi facies, microphthalmia, cardiac, renal, genitouri-
nary defects, thumb and radius deformities [2]. The initial
change at birth in peripheral blood is macrocytosis without
cytopenia. This is followed by thrombocytopenia and
neutropenia. The incidence and prevalence of FA is not
known in Pakistan. Studies from the West reveals that* Correspondence: shabneez.malik@aku.edu
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distribution, and reproduction in any mediumthe incidence of FA is three per million [3]. The only
case that has been reported form our region has been of
FA transformation into acute lymphoblastic leukemia
(ALL) [4].
Due to the increase in chromosomal instability, P53
activation and cell death; there is an increased possibility
of clonal evolution in FA patients [5]. These patients
present with malignancies at a younger age compared to
that of general population and the predominant malignan-
cies are AML, liver tumors, head and neck carcinomas
and gynecological cancers [6]. The highest risk of
myelodysplastic syndrome (MDS) and AML is in young
adulthood [2,7] and they are usually preceded by an aplastic
or hypoplastic phase.
The leukemia in FA differs from that of general popula-
tion. In one retrospective study [8], it was found that
approximately 27% patients presented with AML withouttral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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leukemia was 14 years and the cumulative incidence of
developing leukemia by the age of 29 years was 37%.
Majority of the leukemias were AML (94%), predominantly
acute myelomonocytic leukemia while remaining were
ALL. This is in contrast with 84% of the leukemia being
lymphoid in non-FA patients of similar age group.
We report a case of young male who presented with
AML and based on his physical abnormalities, peripheral
blood was analyzed for chromosomal breaks. He had rare
cytogenetic abnormalities not seen in AML transformed
from FA.
Case presentation
A 17 year old male presented to the emergency with a
history of high grade fever since two weeks. Examination
revealed short stature, tapering jaw (Figure 1A), pallor and
thumb polydactyly (Figure 1B). There was no visceromegaly
or lymphadenopathy. Previous complete blood counts were
not available. Family history was insignificant. Complete
blood count showed haemoglobin 3.4 gm/dl, MCV 100 fl
and MCH 36 pg, white blood cell count 55.9 × 10 E9/L and
platelet 8 × 10E9/L. Peripheral blood smear revealed 26%
blast cells (Figure 2A). Bone marrow was hypercellular
exhibiting infiltration with 21% blast cells comprising of
myeloblasts and monoblasts with presence of auer rods
(Figure 2B). Bone trephine was hypercellular showing
diffuse infiltration with sheets of blast cells. The overall
findings were consistent with acute myelomonocytic
leukemia (AML M-4, according to F.A.B classification). The
blasts cells expressed CD 33, CD13, HLA-DR, CD 117,
CD34 antigens and cytoplasmic myeloperoxidase on
immunophenotyping. Bone marrow cytogenetics revealed
46, XY, t (8:21) (q22; q22) [11]/ 46, XY, add (2) (q37),t
(8; 21) [4]/46 XY [5] (Figure 3). Mutation analysis for
NPM 1 and FLT3 ITD was negative while FLT3 D835
was positive. Based on his physical findings, peripheral
blood was sent for analysis of chromosomal breakage
(Figure 1C). There were 1.98 average number of breaks/Figure 1 Clinical and diagnostic features of the Fanconi anemia patie
(C) Chromosomal breaks in peripheral blood.cell in patient’s cells while control sample had 0.05 average
number of breaks/cell. Tri-radial and complex figures were
also noted. These features were consistent with Fanconi
anemia and the patient was presumed to be transformed
into AML at presentation.
Considering that the patient was high risk AML, option
of subsequent allogeneic bone marrow transplant was
discussed at consolidation therapy. Complete human
leukocyte antigen (HLA) typing of the patient was per-
formed and peripheral blood cytogenetics of his siblings
was advised. He received induction chemotherapy with
daunorubicin and cytarabine (3 + 7). During the hospital
course, he developed febrile neutropenia for which he was
empirically treated with antibiotics. Blood and urine cul-
tures did not reveal growth of organisms. The neutropenia
resolved on Day 21 and the patient became afebrile. Day
14 bone marrow revealed clearance of blast cells while
minimal residual disease showed 0.03% blast cells. He was
discharged and was advised follow up in outpatient clinic.
However the patient was lost to follow up.
Discussion
We have described a case of FA AML (AML that is
presumed to be transformed from FA) with rare cytogen-
etics and poor prognosis due to positivity of FLT3 D835
mutation. AML is 500 fold more likely to develop in FA
patients than the general population [9] and approximately
one third of the patients with FA initially present with
AML [8]. It has been reported that approximately 0.18%
of newly diagnosed AML may have been transformed
from FA [10]. This emphasizes the importance of identi-
fying those patients with FA who are more likely to
transform into AML and bone marrow cytogenetics may
be the effective tool for this purpose. If specific cytogenetic
abnormalities known to be associated with transformation
to AML are known, the individual risk of developing
leukemia can be predicted.
The most frequent chromosomal abnormalities in FA
AML were gain of 1q, monosomy 7, and gain of 3qnt. (A) Fanconi facies with tapering jaw. (B) Polydactyly.
Figure 2 Peripheral blood smear and bone marrow aspirate. (A) Peripheral blood smear showing blast cells. (B) Bone marrow smear
revealing a blast cell exhibiting an Auer rod.
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and trisomy 8 were sole findings in de novo AML [11].
Other abnormalities that are common in the FA AML
group include deletion 7q, gain of 13q, and deletion 20q
[11]. P.A. Mehta et al. [12]. evaluated routine fluorescent
in situ hybridization (FISH) analysis for 1q, 3q, monosomy
7 and 7q deletions on bone marrow samples from FA and
they recommended that patients with small clones (<10%)
should have regular follow up every 3 to 6 months with
bone marrow FISH analysis while patients with large
clones (>10%) and chromosome 7 abnormalities should
undergo HSCT.
Our patient had none of the specific cytogenetic abnor-
malities known for FA AML except for t(8; 21) which is
known to be more frequent in de novo AML and addition
2q, the significance of which is unknown. This indicates
that AML should be considered as a transformation from
FA even in the absence of known cytogenetic abnormalities
for FA AML. This is important since FA cells are highly
sensitive to chemotherapeutic agents leading to a poor
outcome and the need for an early HSCT before trans-
formation to leukemia occurs [7].Figure 3 Bone marrow cytogenetics; Karyogram reveals translocationThe rate of absolute neutrophil count (ANC) recovery
after chemotherapy is known to be associated with certain
cytogenetic abnormalities [10], such as t(8;21) which results
in rapid ANC recovery (within 28 days post induction
chemotherapy), while t(9;11) and t(6;9) (common in FA
AML patients) lead to a delayed ANC recovery (>60 days)
[11]. Our patient had t(8; 21) and he had a rapid ANC
recovery within 21 days. Even though he had a good
cytogenetic marker t(8; 21) for prognosis, the presence of
FLT3 mutation placed him in poor prognostic group.
Literature review has revealed that there have not been
any prospective studies or case reports from our region and
the prevalence of specific cytogenetic abnormalities in our
population needs to be known. It remains unclear in this
case whether the cytogenetic abnormalities in the leukemic
cells were present in the bone marrow prior to the diagno-
sis of leukemia. It is possible that Fanconi Anemia predis-
poses to the evolution of leukemic clones. It also remains
unclear whether routine cytogenetic testing of patients with
FA would identify patients at increased risk of developing
AML and who are in need of HSCT. Systematic long-term
follow-up studies needs to be carried out in our population.(8;21) and addition on chromosome 2 (arrow).
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This case emphasizes the importance of identifying
patients with AML who have transformed from FA in the
absence of specific cytogenetic abnormalities. The recog-
nition of specific cytogenetic abnormalities present in FA
known to predispose to AML is crucial for early HSCT
before transformation to leukemia.
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